---
layout: minimal-medicine
title: Bendamustine
---

# Bendamustine
### Generic Name
Bendamustine

### Usage

Bendamustine is a chemotherapy medication used to treat certain types of blood cancers.  Its primary use is in patients with chronic lymphocytic leukemia (CLL) that has progressed despite, or within six months of, treatment with rituximab (a type of targeted therapy) or a rituximab-containing regimen. It's also approved for treating indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed similarly.  While primarily used for these conditions, bendamustine is sometimes used off-label (meaning not officially approved for this purpose by regulatory bodies) in other lymphomas, such as follicular lymphoma, mantle cell lymphoma, and even in some cases of multiple myeloma and Waldenström's macroglobulinemia, often in combination with other drugs.  The use in these off-label indications is often based on clinical experience and ongoing research.  Always consult with a healthcare professional to determine the appropriateness of bendamustine for a specific situation.

### Dosage

Bendamustine is administered intravenously (IV).  Dosage varies considerably depending on the specific cancer being treated, the patient's body surface area (calculated from height and weight), and whether it's being used as a single agent or in combination with other therapies.  There is no established pediatric dosage.

**Examples of Dosage Regimens (Adult):**  Note that these are examples only, and the actual dosage prescribed will depend on factors evaluated by the oncologist or hematologist.

* **CLL (single agent):** 100 mg/m² on days 1 and 2 of a 28-day cycle, for up to 6 cycles.
* **CLL (with rituximab):** Various combinations and dosages exist depending on whether it's first-line or relapsed/refractory disease. For instance, a common regimen might be 90 mg/m² on days 1 and 2 of a 28-day cycle.
* **Indolent B-cell NHL (single agent):** 120 mg/m² on days 1 and 2 of a 21-day cycle, for up to 8 cycles.
* **Other lymphomas (off-label):** Dosages vary widely depending on the specific lymphoma type and combination therapy used, often involving dosages around 90 mg/m² given over a few days within a longer treatment cycle (e.g., 28- or 35-day cycles).

**Dosage Adjustments:** Dosage adjustments are necessary based on factors like kidney and liver function, and the occurrence of side effects.  A healthcare professional will closely monitor patients and make necessary adjustments.


### Side Effects

Bendamustine, like other chemotherapy drugs, can cause a range of side effects.  The severity and frequency can vary from person to person.

**Common Side Effects:**

* Nausea and vomiting
* Fatigue
* Low blood cell counts (anemia, neutropenia, thrombocytopenia) leading to increased risk of infection and bleeding
* Diarrhea
* Constipation
* Hair loss (although less common than with some other chemotherapy drugs)
* Headache

**Less Common but Serious Side Effects:**

* Severe allergic reactions (anaphylaxis)
* Serious infections
* Liver damage (hepatotoxicity)
* Kidney problems (nephrotoxicity)
* Second cancers (long-term risk)
* Tumor lysis syndrome (rapid breakdown of cancer cells leading to kidney problems)


**Important Note:** If you experience any concerning side effects, contact your doctor immediately.  Prompt attention can help manage side effects and prevent serious complications.


### How it Works

Bendamustine is an alkylating agent, a type of chemotherapy drug that works by damaging the DNA of rapidly dividing cancer cells.  It forms covalent bonds with DNA, preventing the cancer cells from replicating and ultimately leading to their death.  Unlike some alkylating agents, bendamustine has some activity against cells that aren't actively dividing, making it potentially more effective against certain cancers. The exact mechanisms by which it causes cell death are still being researched.


### Precautions

* **Hypersensitivity:** Bendamustine is contraindicated in patients with known hypersensitivity to the drug or its components.
* **Bone Marrow Suppression:** This is a significant risk, leading to low blood counts and an increased chance of infection and bleeding.
* **Kidney and Liver Function:**  Bendamustine should be used cautiously in patients with impaired kidney or liver function; dosage adjustments may be needed.
* **Pregnancy and Breastfeeding:**  Bendamustine is categorized as a pregnancy Category D drug, meaning it poses a risk to the developing fetus.  Breastfeeding should be avoided during treatment.
* **Drug Interactions:**  Potential interactions with other medications exist; thorough discussion with a healthcare provider is crucial.
* **Infusion Reactions:**  Infusion reactions, including allergic reactions, can occur.  Premedication may be necessary to minimize this risk.

### FAQs

* **Q: How long does treatment with bendamustine last?** A: The duration of treatment varies depending on the type and stage of cancer and individual response, usually lasting several months.

* **Q:  Are there long-term side effects associated with bendamustine?** A: As with all chemotherapy drugs, there is a risk of long-term side effects, including an increased risk of developing secondary cancers.  Regular follow-up care is essential for monitoring for these possibilities.

* **Q: How is bendamustine stored?** A:  Follow your pharmacist’s instructions for proper storage.  Generally, medications like this should be kept in the refrigerator and protected from light.

* **Q: What should I do if I miss a dose of bendamustine?** A:  Bendamustine is administered by a healthcare professional in a clinical setting.  Do not attempt to adjust your treatment schedule yourself.  Contact your oncologist or hematologist for guidance.

* **Q: Can I take over-the-counter medications while receiving bendamustine?** A: Always inform your healthcare provider about any over-the-counter medications or supplements you are taking to avoid potential interactions.


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice.  Always consult with a healthcare professional for diagnosis, treatment, and management of any medical condition.  The specific details regarding dosage and administration should be determined and overseen by a qualified oncologist or hematologist.
